Shuttle Pharmaceuticals Holdings EBITDA Growth & History (SHPH)
Shuttle Pharmaceuticals Holdings's calculated EBITDA was −$11.6M for fiscal 2025.
View full Shuttle Pharmaceuticals Holdings company overviewShuttle Pharmaceuticals Holdings annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$11.6M | −$3.9M | — |
| 2024 | 2024-12-31 | −$7.7M | −$1.8M | — |
| 2023 | 2023-12-31 | −$5.9M | −$3.5M | — |
| 2022 | 2022-12-31 | −$2.3M | −$601,080 | — |
| 2021 | 2021-12-31 | −$1.7M | — | — |
Shuttle Pharmaceuticals Holdings quarterly ebitda
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | −$1.6M | $1.4M | — |
| Q4 2025 | 2025-12-31 | −$2.3M | −$532,242 | — |
| Q3 2025 | 2025-09-30 | −$2.3M | $784,834 | — |
| Q2 2025 | 2025-06-30 | −$3.7M | −$2.2M | — |
| Q1 2025 | 2025-03-31 | −$3.0M | −$1.6M | — |
| Q4 2024 | 2024-12-31 | −$1.8M | −$494,491 | — |
| Q3 2024 | 2024-09-30 | −$3.1M | −$1.5M | — |
| Q2 2024 | 2024-06-30 | −$1.5M | −$17,522 | — |
| Q1 2024 | 2024-03-31 | −$1.4M | $160,357 | — |
| Q4 2023 | 2023-12-31 | −$1.3M | −$751,993 | — |
| Q3 2023 | 2023-09-30 | −$1.6M | −$777,405 | — |
| Q2 2023 | 2023-06-30 | −$1.5M | −$1.1M | — |
| Q1 2023 | 2023-03-31 | −$1.5M | −$906,346 | — |
| Q4 2022 | 2022-12-31 | −$528,848 | — | — |
| Q3 2022 | 2022-09-30 | −$819,883 | — | — |
| Q2 2022 | 2022-06-30 | −$352,177 | — | — |
| Q1 2022 | 2022-03-31 | −$636,946 | — | — |
Shuttle Pharmaceuticals Holdings ebitda trends
Between the periods ended 2021-12-31 and 2025-12-31, Shuttle Pharmaceuticals Holdings's ebitda decreased from −$1.7M to −$11.6M, a change of −$9.9M. The latest reported quarter, Q1 2026, shows −$1.6M.
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Shuttle Pharmaceuticals Holdings source filings ↗